Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
Cogent Biosciences, Inc. (COGT) had Cash Flow from Financial Activities of $55.49M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-96.41M |
|
-- |
|
-- |
|
$102.64M |
|
$-102.64M |
|
$6.23M |
|
$-96.41M |
|
$-96.41M |
|
$-96.41M |
|
$-96.41M |
|
$-96.41M |
|
$-96.41M |
|
$-102.64M |
|
$-102.57M |
|
171.00M |
|
171.00M |
|
$-0.52 |
|
$-0.52 |
|
| Balance Sheet Financials | |
$804.82M |
|
$4.78M |
|
$29.73M |
|
$834.55M |
|
$59.30M |
|
$223.46M |
|
$242.86M |
|
$302.16M |
|
$467.63M |
|
$532.39M |
|
$532.39M |
|
171.60M |
|
| Cash Flow Statement Financials | |
$-164.15M |
|
$-22.18M |
|
|
Cash Flow from Financial Activities |
$55.49M |
$312.43M |
|
$181.59M |
|
$-130.84M |
|
$34.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.57 |
|
-- |
|
-- |
|
0.30 |
|
0.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-164.97M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-20.62% |
|
-18.11% |
|
-11.55% |
|
-12.75% |
|
$3.10 |
|
$-0.96 |
|
$-0.96 |
|